drugset
drugset / Trial / NCT05860465

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

NCT05860465 ↗

Phase 2/3 Recruiting 254 enrolled Shanghai Pharmaceuticals Holding Co., Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in the treatment of locally advanced or metastatic breast cancer that progressed on CDK4/6 inhibitor combined with endocrine therapy.

Timeline

Start
2023-09-08
Primary completion
2026-12-01
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject SPH4336 Unknown — Oral
Background Fulvestrant Small molecule — Intravenous
Background Letrozole Other / unclassified — Oral

Indications

breast cancer